King Abdulaziz University

Ashraf B Abdel-Naim

Abdelsattar Mansour Omar

Moustafa Elsayed El-Araby

Azizah M Malebari

Farid Ahmed

Ahmed Esmat

Thikryat Neamatallah

Mohamed A El-Zahabi

Salah G Atteiah

Osama A A Ahmed

Nabil Abdulhafiz Alhakamy

Usama Ahmed Fahmy

Raed Felimban

Waleed Rizg

Hani Zakariah Asfour

Sabrin R M Ibrahim

Basma Ghazi Eid

Mohamed W Alrabei

Mohammed Z Nasrullah

Amgad Khedr

Gamal A Mohamed

A nano-pharmaceutical formulation, comprising zein nanoparticles, icariin (ICA) or a pharmaceutically acceptable salt thereof encapsulated within the zein nanoparticles, at least one solubilizer, wherein the at least one solubilizer comprises D-a-Tocopherol polyethylene glycol 1000 succinate (TPGS), and one or more pharmaceutical penetration enhancers is provided. Methods of enhancing libido by administering a composition as described herein is also provided.

Icariin nano-pharmaceutical formulation

Thioctamer, a nanoconjugate of glatiramer acetate (GA) and thioctic acid (TA), e.g. in the form of nanospheres, is provided as are compositions comprising thioctamer and methods of using the same for wound healing. Application of thioctamer to a wound accelerates wound healing, compared to control wounds that are not treated with the copolymer.

Thioctamer expedites wound healing

Cytotoxic compounds containing a phenyl core, amide link(s), an imidazolinone or a propenamide moiety. Also described are pharmaceutical compositions incorporating the cytotoxic compounds and methods for treating cancer. These compounds are cytotoxic against breast, prostate, and leukemia cancer cell lines via dual inhibition of Src kinases and tubulin.

Chemotherapeutic oxazolone derivatives and pharmaceutical compositions thereof

Anticancer compounds, pharmaceutical compositions thereof, and a method of treating cancer

Anti-cancer compounds having oxazolone derivation

Compounds for the treatment of hyperglycemia and/or diabetes are provided. The compounds, which inhibit the enzyme dipeptidyl peptidase (DPP-4), are based on the structure where n1=0-2 such as 0 or 1; R1 is i) a saturated or unsaturated, substituted or unsubstituted monocyclic aliphatic ring, alone or fused with cyclopropane or cyclobutene, optionally comprising one or more substituents attached to the ring; or ii) a substituted or unsubstituted monocyclic aromatic ring, optionally comprising one or more substituents attached to the ring; R2 is present or absent and if present is: C&#x2550;O; (CH)where n=0-4; S; SO; SO; NR where R&#x2550;H, CHor CHCH; or NH(CH)where n=0-4; and R3 is present or absent and if present is (CH)where n=0-4; S; SO; SO; NR where R&#x2550;H, CHor CHCH; or NH(CH)n where n=0-4; and salts and isomers thereof.

Substituted [1,2,4]triazolo[4,3-a]pyrazines as antidiabetics

Pharmaceutical composition and method of treating cancer

Compounds for the treatment of hyperglycemia and/or diabetes are provided. The compounds, which inhibit the enzyme dipeptidyl peptidase (DPP-4), are based on the structure where X may be present or absent an may be OH, Ar is an aryl group; and n ranges from 0 to 5.

Antidiabetic compounds

Growing community of inventors

Jeddah, Saudi Arabia

Ashraf B Abdel-Naim